TorMagnus Pharmaceuticals
TorMagnus Pharmaceuticals is pioneering targeted drug development strategies by leveraging scientific and computational principles through machine learning. The company focuses on identifying converging pathways and therapeutic targets for Parkinson's disease, which is expected to affect over 1 million patients in the U.S. in the next decade. Their scalable pipeline aims to develop targeted therapies for various forms of Parkinson's disease and potentially other neurodegenerative diseases. By utilizing genetics and computation, they identify novel drug targets, validate them in the lab, and develop small molecule modulators against these targets, positioning themselves as innovators in the pharmaceutical industry.
TorMagnus Pharmaceuticals
TorMagnus Pharmaceuticals is pioneering targeted drug development strategies by leveraging scientific and computational principles through machine learning. The company focuses on identifying converging pathways and therapeutic targets for Parkinson's disease, which is expected to affect over 1 million patients in the U.S. in the next decade. Their scalable pipeline aims to develop targeted therapies for various forms of Parkinson's disease and potentially other neurodegenerative diseases. By utilizing genetics and computation, they identify novel drug targets, validate them in the lab, and develop small molecule modulators against these targets, positioning themselves as innovators in the pharmaceutical industry.
TL;DR
Focus: AI-driven drug discovery for Parkinson's disease and peroxisomal/neurodegenerative disorders
Founded: 2022 (May)
Location: San Francisco, California, United States
Investor signal: Y Combinator led pre-seed (Apr 5, 2023)
Company Overview
Problem Domain
Parkinson's disease and peroxisomal/neurodegenerative disorders
Founded
2022
Industry
Biotechnology
Tech Stack
Funding Track Record
Pre-Seed round closed April 5, 2023; total round amount obfuscated in source
Investor Signal
“Y Combinator led a pre-seed round (Apr 5, 2023)”